Leo Pharma eczema treatment recommended in two UK countries

After postponing the decision in April, the British medicines council NICE has now ruled that Adtralza can be recommended to treat atopic dermatitis.
Photo: Leo Pharma/PR
Photo: Leo Pharma/PR
by christian bundgaard, translated by catherine brett

After months of back and forth, the National Institute for Health and Care Excellence (NICE) has decided that Leo Pharma’s monoclonal antibody Adtralza (tralokinumab) can be recommended as a treatment for moderate to severe eczema.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading